ArticleThe Lancet. Oncology2022

Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial.

John M Pagel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.